INDSWFTLTD

NAVRATTAN MUNJAL has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

��NAVRATTAN MUNJAL��has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India��(Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

VOLTAMP : Ind-Swift Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Disclosure under Regulation 31 under SEBI (SAST) Regulations, 2011 has been submitted.

Promoter of Ind-Swift Limited has informed the Exchange regarding disclosure under Regulation 30 and Regulation 31(4) of SEBI SAST Regulations 2011 as at March 31, 2021.

The Promoter along with PAC has submitted to the Exchange a copy of Annual Disclosure under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares and Takeovers), Regulations, 2011 as on March 31, 2019.

For and behalf of Promoter & Promoters Group has submitted to the Exchange a copy of disclosure under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Essix Biosciences Limited has informed the Exchange a copy of disclosure under Regulation 10(6) in respect of acquisition under Regulation 10 of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Gopal Munjal has submitted to the Exchange vide letter dated April 04, 2017 a copy of disclosure under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Gopal Munjal has submitted to the Exchange vide letter dated April 5, 2016 a copy of disclosure under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Ind-Swift Limited has submitted to the Exchange vide letter dated January 04, 2013 a copy of Disclosure under Regulation 13(4), 13(4A) and 13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992.

VRM Portfolio Pvt. Ltd. has submitted to the Exchange a copy of disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 along with Regulation 13(4), 13(4A) and 13(6) of the SEBI (Prohibition of Insider Trading) Regulations, 1992.

AKJ Portfolio Pvt. Ltd. has submitted to the Exchange a copy of disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 along with a Regulation 13(4), 13(4A) and 13(6) of the SEBI (Prohibition of Insider Trading) Regulations, 1992.

VKM Portfolio Pvt. Ltd. has submitted to the Exchange a copy of disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 along with Regulation 13(4), 13(4A) and 13(6) of the SEBI (Prohibition of Insider Trading) Regulations, 1992.

SRM Portfolio Pvt. Ltd. has submitted to the Exchange a copy of disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 along with Regulation 13(4), 13(4A) and 13(6) of the SEBI (Prohibition of Insider Trading) Regulations, 1992.

Ind-Swift Limited has submitted the Exchange a copy of disclosure under Regulation 13(6) of SEBI (Prohibition of Insider Trading) Regulation, 1992.

Ind-Swift Limited has informed the Exchange that M/s Essix Biosciences Limited has acquired 5,35,000 shares aggregating to 1.44% of the share capital of Ind-Swift Limited on July 20, 2005. The mode of acquisition is Preferential Allotment (Allotment of equity shares upon conversion of Zero Coupon Optionally Convertible Warrants) and the shareholding of M/s Essix Biosciences Limited after the said acquisition is 35,60,340 shares aggregating to 9.58% of the share capital of Ind-Swift Limited.

Ind-Swift Limited has informed the Exchange that Essix Biosciences Limited have acquired 3,63,000 Equity Shares aggregating to 4.99% of the share capital of Ind-Swift Limited on March 31, 2005. The mode of acquisition is Preferential Allotment (Allotment of equity shares upon conversion of Zero Coupon Optionally Convertible Warrants) and the shareholding of Essix Biosciences Limited after the said acquisition is 6,05,068 equity shares aggregating to 8.32% of the share capital of Ind-Swift Limited.